Sivik Global Healthcare LLC Purchases 81,970 Shares of Impax Laboratories, Inc. (IPXL)

Sivik Global Healthcare LLC increased its position in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) by 48.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 250,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 81,970 shares during the quarter. Sivik Global Healthcare LLC owned approximately 0.35% of Impax Laboratories worth $4,025,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. TIAA CREF Investment Management LLC lifted its position in Impax Laboratories by 1.0% in the second quarter. TIAA CREF Investment Management LLC now owns 238,473 shares of the specialty pharmaceutical company’s stock valued at $3,839,000 after buying an additional 2,463 shares during the last quarter. Teachers Advisors LLC lifted its position in Impax Laboratories by 7.5% in the second quarter. Teachers Advisors LLC now owns 131,944 shares of the specialty pharmaceutical company’s stock valued at $2,124,000 after buying an additional 9,159 shares during the last quarter. Swiss National Bank lifted its position in Impax Laboratories by 15.3% in the second quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock valued at $1,882,000 after buying an additional 15,500 shares during the last quarter. Scout Investments Inc. lifted its position in Impax Laboratories by 4.0% in the second quarter. Scout Investments Inc. now owns 95,275 shares of the specialty pharmaceutical company’s stock valued at $1,534,000 after buying an additional 3,675 shares during the last quarter. Finally, Bridge City Capital LLC acquired a new position in Impax Laboratories in the second quarter valued at about $760,000. 86.26% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Sivik Global Healthcare LLC Purchases 81,970 Shares of Impax Laboratories, Inc. (IPXL)” was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.truebluetribune.com/2017/09/17/sivik-global-healthcare-llc-purchases-81970-shares-of-impax-laboratories-inc-ipxl.html.

A number of research analysts have commented on IPXL shares. Deutsche Bank AG set a $21.00 target price on shares of Impax Laboratories and gave the company a “buy” rating in a research report on Monday, July 17th. Cantor Fitzgerald upped their target price on shares of Impax Laboratories from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, September 11th. BMO Capital Markets reaffirmed a “hold” rating and issued a $16.00 target price on shares of Impax Laboratories in a research report on Friday, June 23rd. Zacks Investment Research cut shares of Impax Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Royal Bank Of Canada set a $17.00 target price on shares of Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.16.

Shares of Impax Laboratories, Inc. (NASDAQ IPXL) traded down 3.48% during mid-day trading on Friday, hitting $20.80. 1,702,183 shares of the stock traded hands. Impax Laboratories, Inc. has a one year low of $7.75 and a one year high of $27.29. The stock has a 50 day moving average price of $19.04 and a 200-day moving average price of $15.40. The company’s market cap is $1.49 billion.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The company’s revenue was up 17.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.21 EPS. On average, analysts forecast that Impax Laboratories, Inc. will post $0.70 earnings per share for the current fiscal year.

Impax Laboratories Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply